Denali Therapeutics (DNLI) Return on Capital Employed (2018 - 2026)
Denali Therapeutics (DNLI) posted quarterly Return on Capital Employed of 49.95% for Q1 2026, down 810.0% year-over-year from 7.04% in Q1 2025, and up 9.88% quarter-over-quarter from 55.43% in Q4 2025.
Denali Therapeutics (DNLI) Return on Capital Employed (2018 - 2026) Analysis & Trends
Denali Therapeutics (DNLI) has reported Return on Capital Employed for 9 consecutive years, with 49.95% the latest figure, recorded in Q1 2026.
- In Q1 2026, Return on Capital Employed fell 810.0% year-over-year to 49.95%; the TTM figure through Mar 2026 stood at 49.95% (down 810.0% YoY), while the FY2025 annual figure was 47.83%, down 588.0% from the prior year.
- Return on Capital Employed improved to 49.95% in Q1 2026 per DNLI's latest filing, from 55.43% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 12.67% in Q2 2023 and bottomed at 55.43% in Q4 2025.
- Historically, Return on Capital Employed has averaged 34.06% across 5 years, with a median of 34.77% in 2022.
- Annual changes were most pronounced in 2022 — Return on Capital Employed tumbled 3653 bps — and 2024, when it surged 2278 bps.
- Denali Therapeutics' Return on Capital Employed stood at 34.77% in 2022, then jumped by 49 bps to 17.6% in 2023, then tumbled by 111 bps to 37.15% in 2024, then plunged by 49 bps to 55.43% in 2025, then grew by 10 bps to 49.95% in 2026.
- Business Quant data shows DNLI's Return on Capital Employed at 49.95% in Q1 2026, 55.43% in Q4 2025, and 53.67% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Denali Therapeutics | 3.90 Bn | 3.90 Bn | 3.51 Mn | -48.37% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -48.37% |
| Mar 31, 2026 | -49.95% |
| Dec 31, 2025 | -55.43% |
| Sep 30, 2025 | -53.67% |
| Jun 30, 2025 | -47.31% |
| Mar 31, 2025 | -41.86% |
| Dec 31, 2024 | -37.15% |
| Sep 30, 2024 | -35.23% |
| Jun 30, 2024 | -32.76% |
| Mar 31, 2024 | -15.07% |
| Dec 31, 2023 | -17.60% |
| Sep 30, 2023 | -14.12% |
| Jun 30, 2023 | -12.67% |
| Mar 31, 2023 | -37.85% |
| Dec 31, 2022 | -34.77% |
| Sep 30, 2022 | -34.75% |
| Jun 30, 2022 | -30.32% |
| Mar 31, 2022 | -28.50% |
| Dec 31, 2021 | -28.20% |
| Sep 30, 2021 | 1.79% |